| Elpipodect (MK-8189) Multiple Dose Study in Healthy Volunteers and Schizophrenia Participants (MK-8189-003) (NCT02181803) | Merck Sharp & Dohme LLC | 2014-08-05 |
| Person-Centered Versus Measurement-Based Care in Mental Health (NCT02507349) | University of Pittsburgh | 2014-08-01 |
| Effect of MMFS-202-302 on Cognitive Enhancement in Schizophrenia (NCT02237235) | Northwestern University | 2014-08-01 |
| Prediction of Relapse in Schizophrenia/Schizoaffective Disorder With Smartphones and On-body Sensors (NCT02224430) | University of Alabama at Birmingham | 2014-08-01 |
| Neuronal Effects of Exercise in Schizophrenia (NCT02455193) | University of Colorado, Denver | 2014-08-01 |
| Perceptual Deficits in Schizophrenia (NCT02337439) | VA Connecticut Healthcare System | 2014-08-01 |
| Pharmacokinetic Properties of Various Modified Release Tablet Formulations of Lu AF11167 (NCT02260830) | H. Lundbeck A/S | 2014-08-01 |
| D-serine and Cognitive Remediation in Schizophrenia (NCT02156908) | Nathan Kline Institute for Psychiatric Research | 2014-08-01 |
| The Effect of Nitric Oxide on Spatial Working Memory in Patients With Schizophrenia - Pilot Study (NCT02176044) | King's College London | 2014-08-01 |
| Cognitive Remediation Therapy Within a Secure Forensic Setting (NCT02360813) | Central Mental Hospital | 2014-08-01 |
| Open-label Study to Assess Usability of the Medical Information Device #1 (MIND1) System in Adults With Schizophrenia On Oral Aripiprazole (NCT02219009) | Otsuka Pharmaceutical Development & Commercialization, Inc. | 2014-08-01 |
| Effects of Physical Activity in Psychosis (NCT02205684) | Sykehuset i Vestfold HF | 2014-08-01 |
| Berberine Effects on Clinical Symptoms and Metabolic Disturbance in Patients With Schizophrenia (NCT03548155) | Tianjin Anding Hospital | 2014-07-24 |
| Cannabis, Schizophrenia and Reward: Self-Medication and Agonist Treatment? (NCT01964404) | Dartmouth-Hitchcock Medical Center | 2014-07-01 |
| Testing Effect and Schizophrenia (NCT02150174) | University Hospital, Strasbourg, France | 2014-07-01 |
| Biomarker Strategies for Medication-Enhanced Cognitive Training in Schizophrenia (NCT01555697) | University of California, San Diego | 2014-07-01 |
| Berberine Effect on Cytokine, CRP, Metabolic Disturbance as an Adjunctive Therapy in Schizophrenia Patients (NCT02936414) | Tianjin Anding Hospital | 2014-07-01 |
| Pharmacologically-augmented Cognitive Therapies (PACTs) for Schizophrenia. (NCT02634684) | University of California, San Diego | 2014-07-01 |
| Curcumin as a Novel Treatment to Improve Cognitive Dysfunction in Schizophrenia (NCT02104752) | VA Greater Los Angeles Healthcare System | 2014-07-01 |
| Prednisolone Addition for Patients With Recent-onset Psychotic Disorder (NCT02949232) | UMC Utrecht | 2014-07-01 |
| The BC Psychosis Program Biobank and Database for Genetic Polymorphisms and Their Associations With Psychosis Disorder (NCT02322918) | University of British Columbia | 2014-07-01 |
| Enhancing Motivation in Recent Onset Schizophrenia (NCT01817387) | University of California, San Francisco | 2014-07-01 |
| A Multicenter Open-label Study Investigating the Pharmacokinetics and Safety of Aripiprazole IM Depot Formulation (OPC-14597 IMD) During Repeated Administration by Injection Into the Deltoid Muscle in Patients With Schizophrenia (NCT02220712) | Otsuka Pharmaceutical Co., Ltd. | 2014-07-01 |
| Improving Negative Symptoms of Psychosis In Real-world Environments (NCT02170051) | University of California, San Diego | 2014-07-01 |
| A Safety, Tolerability, PK and PD Study of Multiple Oral Doses of SKL15508 in Subjects With Stable Schizophrenia (NCT02205099) | SK Life Science, Inc. | 2014-07-01 |
| Cognitive and Emotional Factors in Visual Exploration Among Patients With Schizophrenia (NCT02874482) | University Hospital, Lille | 2014-07-01 |
| A System for Preference Assessment in Mental Health (NCT02183844) | University of California, Los Angeles | 2014-06-16 |
| Self Directed Positive Parenting Program (Triple P) for Psychosis: A Clinical Case Series (NCT02199704) | University of Manchester | 2014-06-01 |
| A Pilot, Proof-of-concept Cohort Study of the Prevalence of Comorbid Mental Illness and Substance Abuse (NCT02476877) | Advanced Clinical Laboratory Solutions, Inc. | 2014-06-01 |
| Long Term Study of RBP 7000 in the Treatment of Subjects With Schizophrenia (NCT02203838) | Indivior Inc. | 2014-06-01 |
| Adaptive Phase II Study to Evaluate the Safety & Efficacy of NaBen® (NCT01908192) | SyneuRx International (Taiwan) Corp | 2014-06-01 |
| Study to Assess the Safety, Tolerability, Pharmacokinetic (PK) and Pharmacodynamic (PD) Effects of EVP-6308 and the Potential of EVP-6308 to Affect the PK Properties of the Antipsychotic Regimen in Subjects With Schizophrenia Currently Receiving Stable Treatment With up to 2 Atypical Antipsychotics (NCT02037074) | FORUM Pharmaceuticals Inc | 2014-06-01 |
| F17464 in Acute Schizophrenia Trial (NCT02151656) | Pierre Fabre Medicament | 2014-06-01 |
| Metformin in Co-morbid Diabetes or Prediabetes and Serious Mental Illness (NCT02167620) | Centre for Addiction and Mental Health | 2014-06-01 |
| Electroconvulsive Therapy in Clozapine-resistant Schizophrenia (NCT02159001) | Niuvanniemi Hospital | 2014-06-01 |
| Effectiveness of Second Generation Antipsychotics in First Episode Psychosis Patients: 3-year Follow-up (NCT03090503) | Fundación Marques de Valdecilla | 2014-06-01 |
| the Phenotypic and Genetic Profile of Patients With Early Onset Schizophrenia Associated With Autism Spectrum Disorder. (NCT02565524) | Fondation Lenval | 2014-05-18 |
| Study on Abnormal Dopamine Synthesis and Connectivity According to the Antipsychotic Treatment Response in Schizophrenia (NCT02248987) | Seoul National University Hospital | 2014-05-01 |
| A Study of ALKS 3831 in Subjects With Schizophrenia and Alcohol Use Disorder (NCT02161718) | Alkermes, Inc. | 2014-05-01 |
| A Concierge Model of CAE Plus LAI in Individuals With Schizophrenia at Risk for Treatment Non-adherence and Homelessness (NCT02085447) | University Hospitals Cleveland Medical Center | 2014-05-01 |
| Effectiveness of Second Generation Antipsychotics in First Episode Psychosis Patients: 1-year Follow-up (NCT02532491) | Fundación Marques de Valdecilla | 2014-05-01 |
| Efficacy of Metacognitive Training Single Modules: Jumping to Conclusions and To Empathize... (NCT02748486) | University of Warsaw | 2014-05-01 |
| Retrieval Practice and Schizophrenia (NCT02108899) | University Hospital, Strasbourg, France | 2014-05-01 |
| Real Life Assessment of Abilify Maintena (NCT02131415) | Lundbeck Canada Inc. | 2014-05-01 |
| Intensive Transcranial Magnetic Stimulation for Negative Symptoms in Schizophrenia (NCT02127879) | Brno University Hospital | 2014-05-01 |
| Integrated Metacognitive Therapy in First Episode Psychosis (NCT02131116) | Indiana University | 2014-05-01 |
| rTMS in First Episode Psychosis (NCT02131129) | Indiana University | 2014-04-30 |
| The Mechanism of TCF7L2 and SLC30A8 on Antipsychotic-induced Metabolic Syndrome (NCT02093858) | Central South University | 2014-04-01 |
| Treatment of Negative Symptoms and Schizophrenia (NCT02204787) | University Hospital, Montpellier | 2014-04-01 |
| Enhancing Social Interaction With an AlterEgo Artificial Agent (NCT02879591) | University Hospital, Montpellier | 2014-04-01 |
| Randomized Controlled Trial (RCT) of a Motivational Decision Support System (NCT02086162) | Dartmouth-Hitchcock Medical Center | 2014-04-01 |
| Pharmacokinetic Study of Lurasidone After Multiple Oral Administration in Healthy Human Subjects (NCT02174523) | Marubeni Pharmaceuticals (Suzhou) Co., Ltd. | 2014-04-01 |
| Transcranial Direct-current Stimulation (tDCS) in Treatment Refractory Auditory Hallucinations (NCT03485131) | Manhattan Psychiatric Center | 2014-04-01 |
| Biological Evaluation of Dietary Supplement Liposomal Glutathione (NCT01967667) | University of Maryland, Baltimore | 2014-04-01 |
| Randomized, Double-blind, Placebo Controlled, Multi-center and Tolerability of RBP-7000 in Schizophrenia Patients (NCT02109562) | Indivior Inc. | 2014-04-01 |
| Project Bridge: Peer Health Navigator Intervention (NCT02022462) | University of Southern California | 2014-04-01 |
| A Double-Blind Trial of Adjunctive Valacyclovir to Improve Cognition in Early Phase Schizophrenia (NCT02008773) | Indiana University | 2014-03-26 |
| Skills for Wellness (NCT01980147) | Nova Scotia Health Authority | 2014-03-22 |
| Famotidine in Schizophrenia (NCT01946295) | Jesper Ekelund | 2014-03-01 |
| Roflumilast Plus Antipsychotics Proof of Mechanism Study in Schizophrenia (NCT02079844) | Takeda | 2014-03-01 |
| Problem-solving-based Bibliotherapy Program for Family Caregivers (NCT02391649) | Chinese University of Hong Kong | 2014-03-01 |
| Study Assessing SEP-363856 in Male and Female Volunteers With High or Low Schizotype Characteristics (NCT01972711) | Otsuka Pharmaceutical Development & Commercialization, Inc. | 2014-03-01 |
| Pharmacokinetics and Tolerability Study of Risperidone ISM® in Schizophrenia (NCT02086786) | Rovi Pharmaceuticals Laboratories | 2014-03-01 |
| Adherence to Treatment, Safety and Tolerability Study of the Medical Information Device #1 (MIND1) in Subjects With Schizophrenia or Bipolar I Disorder (NCT01981811) | Otsuka Pharmaceutical Development & Commercialization, Inc. | 2014-03-01 |
| Resveratrol, Cardiovascular Risk Markers And Cognitive Performance In Patients With Schizophrenia (NCT02062190) | Federal University of Rio Grande do Sul | 2014-03-01 |
| tDCS & Auditory Hallucinations in Schizophrenia (NCT02227563) | Herzog Hospital | 2014-03-01 |
| Psychosocial Intervention to Reduce Self-stigma and Improve Quality of Life Among People With Mental Illness in Chile (NCT03197168) | University of Chile | 2014-03-01 |
| Implementation of Illness Management and Recovery in Mental Health Services (NCT02077829) | University Hospital, Akershus | 2014-03-01 |
| A Pharmacokinetic Study of Lurasidone After Single Oral Administration in Healthy Subjects (NCT02174510) | Marubeni Pharmaceuticals (Suzhou) Co., Ltd. | 2014-03-01 |
| A Study of GWP42003 as Adjunctive Therapy in the First Line Treatment of Schizophrenia or Related Psychotic Disorder (NCT02006628) | Jazz Pharmaceuticals | 2014-02-25 |
| Tandospirone Combined With Atypical Antipsychotic Drugs in Schizophrenia (NCT02040883) | Qingyun Yin | 2014-02-01 |
| Critical Time Intervention-Task Shifting: Randomized Controlled Trial (NCT01995864) | Columbia University | 2014-02-01 |
| Low and High Frequency Repetitive Transcranial Magnetic Stimulation (rTMS) in the Treatment of Resistant Auditory Hallucination in Schizophrenia (NCT02175251) | Assistance Publique - Hôpitaux de Paris | 2014-02-01 |
| D-Cycloserine Augmentation of Cognitive Behavioral Therapy for Delusions (NCT01981759) | NYU Langone Health | 2014-02-01 |
| STEP-ED: Reducing Duration of Untreated Psychosis and Its Impact in the U.S. (NCT02069925) | Yale University | 2014-02-01 |
| Brexpiprazole (OPC-34712) Trial in the Treatment of Adults With Acute Schizophrenia (NCT02054702) | Otsuka Pharmaceutical Development & Commercialization, Inc. | 2014-02-01 |
| Emotions in Schizophrenia and Bipolar Disorders: a Common Vulnerability? (NCT02805088) | CHU de Reims | 2014-02-01 |
| Parallel Group, Multiple Dose Pharmacokinetics Study of Five Antipsychotic Medications in Psychiatric Participants (NCT02087579) | Janssen Research & Development, LLC | 2014-02-01 |
| Effect of Memantine on ERP in Early Schizophrenia and Healthy Subjects (NCT02233556) | National Taiwan University Hospital | 2014-02-01 |
| Tocilizumab as Add-On Treatment For Residual Positive, Negative, and Cognitive Symptoms of Schizophrenia (NCT02034474) | New York State Psychiatric Institute | 2014-02-01 |
| A Study of the Safety, Tolerability and Pharmacokientics of RO5545965 in Patients With Schizophrenia on Risperidone (NCT02019329) | Hoffmann-La Roche | 2014-01-01 |
| Pilot-trial of Emotion-focused Cognitive Behavior Therapy for Patients With Schizophrenia (NCT02787122) | Philipps University Marburg | 2014-01-01 |
| eVAluatIon of OLanzapine TreatmEnT (NCT02006862) | Elpen Pharmaceutical Co. Inc. | 2014-01-01 |
| Computerized Cognitive Training for Schizophrenia in Brazil (NCT02591498) | Universidade Federal do Rio de Janeiro | 2014-01-01 |
| Nicotine Receptor Density & Response to Nicotine Patch: Pt 2 Extended Treatment (NCT02676375) | Brentwood Biomedical Research Institute | 2014-01-01 |
| Glutamate, Brain Connectivity and Duration of Untreated Psychosis (NCT02034253) | University of Alabama at Birmingham | 2014-01-01 |
| Oxytocin and CBSST for People With Schizophrenia (NCT01752712) | University of Maryland, Baltimore | 2014-01-01 |
| Transcranial Current Stimulation as a Treatment for Auditory Hallucinations in Schizophrenia (NCT01963676) | University of North Carolina, Chapel Hill | 2014-01-01 |
| Measuring the Effect of Remote Monitoring of Treatment Adherence on the Risk of Re-admission of Ambulatory Schizophrenic Patients (NCT01729572) | Shalvata Mental Health Center | 2014-01-01 |
| Autobiographical Memory Organization in Schizophrenia (NCT02570594) | University Hospital, Strasbourg, France | 2014-01-01 |
| Probing the Cannabinoid System in Individuals With a Family History of Psychosis (NCT02102113) | Yale University | 2014-01-01 |
| Memantine add-on for Cognitive and Negative Symptoms of Schizophrenia (NCT02001103) | National Taiwan University Hospital | 2014-01-01 |
| Association of Amisulpride Response in Schizophrenia With Brain Image (NCT02095938) | CHA University | 2014-01-01 |
| Pan European Collaboration on Antipsychotic Naïve Schizophrenia II (NCT02339844) | University of Copenhagen | 2014-01-01 |
| Oxytocin as Adjunctive Therapy for Schizophrenia (NCT01699997) | IRCCS Centro San Giovanni di Dio Fatebenefratelli | 2014-01-01 |
| RCT of Methotrexate Added to Treatment As Usual in Schizophrenia (NCT02074319) | Pakistan Institute of Living and Learning | 2013-12-01 |
| Emotional Intelligence in Schizophrenia and Bipolar-I- Disorder (NCT01998516) | Medical University Innsbruck | 2013-12-01 |
| Neuroendocrine and Metabolite Substrates in Schizophrenia (NCT02423096) | Chang Gung Memorial Hospital | 2013-12-01 |
| Effects of a Psycho-corporal Training on Postural and Cognitive Dual-task Performances in Patients With Schizophrenia (NCT03280810) | Centre Hospitalier Universitaire de Saint Etienne | 2013-12-01 |
| Open-Label Observational Pilot Study to Evaluate the Pharmacokinetics of Aripiprazole in Subjects With Bipolar 1 Disorder or Schizophrenia (NCT02050854) | Otsuka Pharmaceutical Development & Commercialization, Inc. | 2013-12-01 |